Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study

the aims of SACHA study was to appreciate prevalence, evolution and follow-up, treatment response of patients with acquired hemophilia with biological and clinical data. Inclusion criteria were factor VIIIc below 30% associated with presence of Facgteur VIII inhibitor (titer > 1 u Bethesda. Clinical and biologival data were obtained at Day 0 (as soon as possible and at 1, 3, 6 and 12 months.Informations were notified to co-investigators with the help of two french medical society (Internal medicine, french haemostasis and thrombosis society.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acquired Haemophilia Register

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Rouen

Rouen, 76031, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Factor VIIIc < 30% and Factor VIII inhibitor > 1 u Bethesda

Exclusion criteria

absence and signed consent, haemophilia A

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Important dates

Study start: 2001
Study completion: 2006
First posted: Sep 21, 2005
Registry last updated: Jun 18, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed